BERLIN – German pharmaceutical giant Bayer is examining whether it could help CureVac develop its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday.
Although vaccination campaigns have begun around the world using various COVID-19 vaccines, many countries say that the ability to fire a weapon is limited by lower-than-expected stocks due to a lack of production.
“We are ready to get out of all the stops for that,” Werner Baumann told Welt am Sonntag.
“This is not about financial reasons, but about making the vaccine available as soon as possible.”
Bayer agreed this month to help German company CureVac develop its candidate for the COVID-19 vaccine, which is in the final clinical trials but has not yet been approved.
Bauman said the pharmacist was “intensively exploring” expanding its partnership to include the production of CureVac vaccines.
“In Germany, with our manufacturing network in the United States, we could have produced more vaccines in principle,” he said.
On Friday, US pharmacist Pfizer announced that there would be a temporary slowdown in vaccine shipments, which he developed with German partner BioNTech, citing changes in production processes to boost production.